Concordance of Hypermethylated DNA and the Tumor Markers CA 15-3, CEA, and TPA in Serum during Monitoring of Patients with Advanced Breast Cancer

Table 1

Distribution of metastasis before and after therapy among the 29 investigated patients.

	Start of therapy	End of therapy
Lung	31.0%; (9/29)	24.1%; (7/29)
Liver	3.4%; (1/29)	13.8%; (4/29)
Contralateral mamma	3.4%; (1/29)	0.0%; (0/29)
Bone	44.8%; (13/29)	48.3%; (14/29)
Intra-abdominal	3.4%; (1/29)	3.4%; (1/29)
Skin	20.7%; (6/29)	10.3%; (3/29)
Lymph node	48.3%; (14/29)	20.7%; (6/29)
Other locations	13.8%; (4/29)	17.2%; (5/29)
CNS	n.d.	3.4%; (1/29)
Solitary location	20.7%; (6/29)	6.9%; (2/29)
Multiple location	75.9%; (22/29)	69.0%; (20/29)